Assessment of Cardiovascular System in Iraqi Patients with Renal Failure

Abstract

BackgroundPatients with kidney disease have a higher risk of cardiovascular morbidity and mortality especially the patients with ESRD and those on dialysis.  N-terminal pro-brain natriuretic peptide (NT-proBNP) is widely used to monitor cardiac disease, but it is very dependent on (GFR). the soluble Suppression of Tumorigenicty2 (sST2) and (NT-proBNP) are important biomarkers for risk-identifying cardiovascular (CV) events in patients with renal disease.  The aims of this study were to examine the predicting of cardiovascular disease events in CKD patients.

Method: This study consists of a total (90) subjects, among them (G1) thirty patients on dialysis, (G2) thirty patients newly diagnosed, and (G3) thirty healthy subjects that served as a control group. This study has been carried out in AL-Yarmok Teaching Hospital and AL-Karama Teaching Hospital in Baghdad for the period from October 2020 till January 2021.  sST2, NT-proBNP was measured by ELISA kit. eGFR measured by utilizing the (MDRD) study equation "modification of Diet in Renal Disease".

The results appeared highly significant (p<0.05) in sST2, and NT-proBNP levels in serum of patients receiving hemodialysis but non-significant difference (p>0.05) in the newly diagnosed patients.

Conclusion:The levels of cardiac biomarkers (sst2 and NT-proBNP) have risen in patients on dialysis comparing with the control that predicts cardiovascular disease (CVD). This elevation was absent in the newly diagnosed group.